Disseminierte kutane Beteiligung bei Churg-Strauss-Syndrom unter Omalizumab-Therapie

We report on a 48-years old caucasian female patient with severe recalcitrant IgE-mediated bronchial asthma who developed a Churg-Strauss syndrome with rapid progression of marked cutaneous involvement of the erythema migrans type 7 weeks after start of a therapy with omalizumab, a humanized monoclonal antibody directed against IgE (Xolair ® ).